Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
about
Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapyPredictors of Treatment Failure in HIV-Positive Children Receiving Combination Antiretroviral Therapy: Cohort Data From Mozambique and Uganda.Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity.When to start antiretroviral therapy in resource-limited settings: a human rights analysis.Transmitted drug resistance in nonsubtype B HIV-1 infection.Re-thinking global health sector efforts for HIV and tuberculosis epidemic control: promoting integration of programme activities within a strengthened health system.Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets.A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects.Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings.Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa.Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries.Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings.The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients.Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children.Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South AfricaRates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South AfricaEffectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patientsDevelopment, Validation, and Field-Testing of an Instrument for Clinical Assessment of HIV-Associated Neuropathy and Neuropathic Pain in Resource-Restricted and Large Population Study SettingsShort communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Côte d'IvoireGlobal challenges in the development and delivery of paediatric antiretrovirals.Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South AfricaEffectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya.Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathyAssociation Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients.Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda.Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges.HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa.Growing challenges for HIV programmes in Asia: clinic population trends, 2003-2013.Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability.Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation.Universal access to HIV treatment in the context of vulnerability: female farm workers in Zimbabwe.Depressive symptoms and exposure to efavirenz in West African HIV-infected adults.
P2860
Q24234853-702CD007-B776-43C7-815F-D23126FC45EEQ30997469-100DB38E-8BA9-45D3-A24B-C63940E3DA77Q33375532-DB5498B3-DE9F-4A9C-8221-26115AEC77E2Q33394513-2057EBA4-0551-45F0-AEA4-CF5D411F2D20Q33548096-A6F294FC-6489-48A7-AC09-780032AA687CQ33567164-EFD0241D-B634-4099-8DD4-4654F0792A32Q33625404-471070F5-07CB-4C59-814E-9845267439D5Q33807615-B3312809-6DA2-42BE-80E9-08BE43D83E43Q33907223-A91A0485-9F9B-471C-8D86-1A0918B474EAQ34020969-A083C5D9-1325-48E6-B762-677596CDCF3CQ34208678-5DC9439C-826A-4AD8-819B-2315EBED1587Q34320076-F5EFCD70-B82D-4B1C-BB75-9AF0124F9448Q34687565-62800F59-400E-4398-8490-8B9803DA5F74Q34730606-8681EA57-DAD4-48DE-8A7A-98D4D424BDD2Q34840325-6A0ABAFC-FE62-41A6-AB9B-93A6DFB9E5A2Q34938054-3E98BABB-F4F9-4A31-B2BF-BD321D59007AQ35083506-3E9DB93E-8BD3-4C08-BA7E-06D422D77696Q35179391-7CE6EB54-7A82-4AE4-898F-8C1C6E8EAE85Q35549604-CF040631-70E3-4A40-90DC-47DC029D630FQ35856520-420C2512-DA77-42C0-9E7D-1663EE7AE310Q36083869-51BEC1A3-5E45-45A1-A84F-FCBBF9C2AF0AQ36091962-DC28FB49-8ABF-4009-8C99-9C1FDCE47D6CQ36169291-8C9266CE-8D6A-4FD1-91EF-8EC68D6ECA98Q36493488-9FCD74DA-DE4E-4A33-A8B5-3026A8E2969BQ36800408-77A93EC3-677E-462A-A82A-2ECC7158FDE8Q36870758-00821AEA-B9C6-48FF-B3C0-D521D1F6BC05Q37246513-9170A1D3-8CE0-4212-9C14-7EB1B2955079Q37251569-108C6D4F-882C-4C98-ACCC-EF3F48E81A15Q37302739-F576D67E-D46B-4F1D-91A7-C709F2B87896Q37359827-4DF5B531-0559-4D9A-8F5F-009AC3895CFCQ37415603-3F6FB095-D34C-4358-AD7B-4A90D3A1AA6AQ37419984-82E7D901-FF06-42AC-9773-2BC8C3089A80Q38403063-9C48D0EC-A917-4866-B694-F4499618FFCBQ38452483-1A590976-1231-4DD5-BB20-FBD3A483C6E3Q41071212-002AB8A2-0F13-4954-9096-0079F898C475Q42252232-EE62367D-4296-4C57-BACA-9BA451F4EB5CQ46127982-9E19AD1E-BA78-4D60-BCFE-559D4E47F402
P2860
Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Use of antiretroviral therapy ...... rst- and second-line regimens.
@en
type
label
Use of antiretroviral therapy ...... rst- and second-line regimens.
@en
prefLabel
Use of antiretroviral therapy ...... rst- and second-line regimens.
@en
P2093
P1433
P1476
Use of antiretroviral therapy ...... rst- and second-line regimens.
@en
P2093
Badara Samb
Boniface Dongmo Nguimfack
Françoise Renaud-Théry
Joseph Perriëns
Marco Vitoria
Peter Graaff
P304
P356
10.1097/01.AIDS.0000279711.54922.F0
P407
P478
21 Suppl 4
P577
2007-07-01T00:00:00Z